Trial · NCT03618030

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03618030, Phase 3, Completed, Purdue Pharma, Canada; results first posted 2021-07-26

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD). Trials, record NCT03618030. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03618030

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT number: NCT03618030
Status: Completed
Phases: Phase 3
Enrollment: 288 participants, actual
Lead sponsor: Purdue Pharma, Canada
Conditions: ADHD
Interventions: PRC-063 oral capsules, Placebo oral capsules
First posted: 2018-08-07
Last updated: 2021-07-26
Results first posted: 2021-07-26

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Post-dose PERMP-T (Permanent Measure of Productivity - Total Score) Scores Measured During the Full-day Adult Laboratory Classroom Visit	Full-day ALC - 13 hours	PERMP-T measures the number of completed and number of attempted math problems completed during a 10 minute test. The scale ranges from 0 to 800, with a higher score indicating a better outcome.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Post-dose PERMP-T (Permanent Measure of Productivity - Total Score) Scores Measured During the Full-day Adult Laboratory Classroom Visit	Full-day ALC - 13 hours	The full analysis (FA) population was the group of subjects who were randomized and received at least one dose of double-blind study drug, attended the full-day ALC visit evaluation, and had at least one post-dose PERMP-T evaluation during the full-day ALC visit. The primary efficacy endpoint compared all doses of PRC-063 versus Placebo.	score on a scale	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Post-dose PERMP-T (Permanent Measure of Productivity - Total Score) Scores Measured During the Full-day Adult Laboratory Classroom Visit	Double-Blind Active Treatment		302.9	Standard Error 3.50	score on a scale
Post-dose PERMP-T (Permanent Measure of Productivity - Total Score) Scores Measured During the Full-day Adult Laboratory Classroom Visit	Double-Blind Placebo Treatment		286.6	Standard Error 3.52	score on a scale

Source ClinicalTrials.gov

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	PRC-063 25 mg	15
Overall Study	STARTED	PRC-063 35 mg	14
Overall Study	STARTED	PRC-063 45 mg	21
Overall Study	STARTED	PRC-063 55 mg	39
Overall Study	STARTED	PRC-063 70 mg	36
Overall Study	STARTED	PRC-063 85 mg	27
Overall Study	STARTED	PRC-063 100 mg	18
Overall Study	STARTED	Placebo Treatment	118
Overall Study	COMPLETED	PRC-063 25 mg	3
Overall Study	COMPLETED	PRC-063 35 mg	3

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events99

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headache	Nervous system disorders	Dose-Optimization	61	285
other	Headache	Nervous system disorders	Double-Blind PRC-063 25 mg	0	3
other	Headache	Nervous system disorders	Double-Blind PRC-063 35 mg	0	4
other	Headache	Nervous system disorders	Double-Blind PRC-063 45 mg	1	15
other	Headache	Nervous system disorders	Double-Blind PRC-063 55 mg	0	31
other	Headache	Nervous system disorders	Double-Blind PRC-063 70 mg	1	30
other	Headache	Nervous system disorders	Double-Blind PRC-063 85 mg	1	22
other	Headache	Nervous system disorders	Double-Blind PRC-063 100 mg	2	16
other	Headache	Nervous system disorders	Double-Blind Placebo Treatment	3	118
other	Decreased Appetite	Metabolism and nutrition disorders	Dose-Optimization	61	285

1 to 10 of 99Source ClinicalTrials.gov

See all 99 adverse events

Adverse event totals27

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dose-Optimization	0	285
Total, all-cause mortality	Double-Blind PRC-063 25 mg	0	3
Total, all-cause mortality	Double-Blind PRC-063 35 mg	0	4
Total, all-cause mortality	Double-Blind PRC-063 45 mg	0	15
Total, all-cause mortality	Double-Blind PRC-063 55 mg	0	31
Total, all-cause mortality	Double-Blind PRC-063 70 mg	0	30
Total, all-cause mortality	Double-Blind PRC-063 85 mg	0	22
Total, all-cause mortality	Double-Blind PRC-063 100 mg	0	16
Total, all-cause mortality	Double-Blind Placebo Treatment	0	118
Total, other adverse events	Dose-Optimization	167	285

1 to 10 of 27Source ClinicalTrials.gov

See all 27 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
34189995	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03618030

GET https://conductscience.org/api/trials/v1/NCT03618030/flow?page=2

API reference For AI assistants